The first "Chinese-origin" monoclonal antibody succeeded in entering the international market and gained approval from the US FDA for listing.

On September 2nd, Fuhong Hanlin announced that two products developed and produced by the company, Denosumab Injection for Injection, have been approved by the U.S. FDA for listing, which are used for the treatment of osteoporosis and eight other indications related to bone events. This also marks the first domestically produced Denosumab to be approved overseas. Currently, Fuhong Hanlin has three products approved in the United States.